Navigation Links
OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Date:2/15/2008

improve treatment outcomes in second-line prostate cancer," said Dr. Fred Saad, who is also the primary investigator in the study. "The data also suggests that retreatment with docetaxel when combined with OGX-011 may reverse chemotherapy resistance in second-line docetaxel retreatment. We look forward to confirming these data in planned Phase 3 studies."

About OGX-011

OGX-011 is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer indications and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration. Clusterin levels may be further increased in response to standard cancer therapies, including hormone ablation therapy, chemotherapy and radiation therapy. Clusterin expression is linked to disease progression, treatment resistance, poor prognosis and survival in scientific publications. For example, increased expression of clusterin in prostate cancer is closely correlated with increasing Gleason score, which is a strong prognostic factor for poor survival of patients with prostate cancer.

About OncoGenex

OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. O
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 , The first ... for Paediatric Endocrinology (ESPE) Meeting  Investment supports ... research in the field of growth  , ... Germany , today announced the first recipients ... The awards were announced during a Satellite Symposium organized ...
(Date:9/18/2014)... September 18, 2014 Bipartisan passage this ... bill designed to stimulate development and commercialization of new ... praised by leaders of SPIE, the international society ... American Manufacturing and Innovation (RAMI) Act, now moves to ... have said they are optimistic that it will win ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... A novel robotic system that can operate ... being tested as part of a biomedical research partnership ... the aim of determining if the robot, in conjunction ... faster, more accurate, less costly, and less discomforting for ... to deliver prostate cancer therapies with greater precision. , ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3POCT Market in China 2014-2018 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... MSC Care Management, the industry,s leading provider ... post-injury workers, compensation claimants nationwide, announced today that ... company also focused on the workers, compensation industry, ... cost management solution, known as S3. Integrated Healthcare ...
... Ind., Oct. 4, 2011 Kylin Therapeutics, Inc., ... it has received a notice of allowance from ... its second U.S. patent application. This newly allowed ... well as expanded areas on Kylin,s proprietary nanoparticle ...
... to Advance Development of Creabilis, First-in-Class Products ... unmet medical needs in dermatology, inflammation and pain, has ... funding round led by Abbott Biotech Ventures. Existing investors ... investors, joined the round. The new funds will be ...
Cached Biology Technology:MSC to Offer Surgical Implant Cost Management Solution through Acquisition of Integrated Healthcare Services 2Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology 2Creabilis Raises €15M ($20M) in Series B Fundraising Round 2
(Date:9/18/2014)... International Space Station ever starts a "frequent flyers" program, ... Recently the orbiting laboratory has hosted increasing numbers of ... from the space station in April, and another is ... experiment is planned to launch in December. , Fruit ... the world-- and in space. Model organisms can reveal ...
(Date:9/18/2014)... fall foliage season that prompts millions of Americans to undertake ... and possibly last a little longer within a century, according ... peeping in some areas of the United States as summer ... in the journal Global Ecology and Biogeography . For ... is the state tree of New Hampshire could change ...
(Date:9/18/2014)... is stored in DNA, tiny strands of nucleic acid ... To express this genetic data, our DNA is copied ... proteins that perform tasks in our cells. , ... RNA molecule. Unlike all other known RNAs, this molecule ... molecules are abundant, little has been known about how ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... Beyond the simple stream of one-letter characters in the ... In order to decipher this level of architecture, scientists ... detect copy number variants (CNVs)--defined as large deletions and ... the journal Genome Research --were used to create ...
... behind the dramatic increase in testicular cancer, now ... men, is the focus of a five-year, $5.5 ... Public Health researcher Tongzhang Zheng. , Testicular cancer ... will provide important information on possible environmental, genetic ...
... Helping to change scientists' thinking about how the heart is ... of stem cell that is the precursor to at least ... cardiac progenitor cell gives rise to both myocardial cells, which ... heart, and to the vascular smooth muscle cells that line ...
Cached Biology News:New technology used to construct the first map of structural variation in the human genome 2Getting to the heart of the heart 2Getting to the heart of the heart 3
IkappaB-alpha (112B2) Mouse mAb...
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Biology Products: